Researchers develop novel antibody fragments against SARS coronavirus-2
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These nanobodies are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
They therefore penetrate the tissue better and can be produced more easily in larger quantities. The researchers at the University Hospital Bonn have also combined the nanobodies into potentially particularly effective molecules. These attack different parts of the virus simultaneously. The approach could prevent the pathogen from evading the active agent through mutations. The results are published in the journal Science.